Callan Capital’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Callan Capital’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-7,598	Closed	-$143K	–	79
2015 Q2	$143K	Sell	7,598 -500	-6%	-$9.62K	0.03%	65
2015 Q1	$157K	Sell	8,098 -1,750	-18%	-$43.9K	0.03%	65
2014 Q4	$288K	Hold	9,848	–	–	0.07%	64
2014 Q3	$351K	Hold	9,848	–	–	0.1%	54
2014 Q2	$441K	Buy	9,848 +8,098	+463%	+$391K	0.12%	50
2014 Q1	$85K	Hold	1,750	–	–	0.03%	49
2013 Q4	$65K	Hold	1,750	–	–	0.02%	46
2013 Q3	$180K	Sell	1,750 -523	-23%	-$57.4K	0.09%	38
2013 Q2	$176K	Buy	+2,273	New	+$218K	0.1%	32

Other funds holding IMUC

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

FAAS

First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Callan Capital's IMUC Position: Q3 2015 in Review

Callan Capital sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q3 2015, closing a stake of 7,598 shares — an estimated $143K sold.

Callan Capital first reported a position in IMUC in Q2 2013 and held it in 9 quarters. The position peaked at $441K in Q2 2014. 28 funds tracked by Wall St. Rank hold IMUC as of Q3 2015.

Callan Capital reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q3 2015 after selling out during the quarter.
Callan Capital sold 7,598 ImmunoCellular Therapeutics, Ltd. shares in Q3 2015, an estimated $143K.
Callan Capital first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 9 quarters.
Callan Capital's ImmunoCellular Therapeutics, Ltd. position peaked at $441K in Q2 2014.
28 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q3 2015.

Based on Callan Capital's 13F filing for Q3 2015, filed 10 Nov 2015.